```html

Quasi‑epidemic Thyroiditis: A Complete Patient Guide

Overview

Quasi‑epidemic thyroiditis is a term used to describe a sudden, cluster‑type increase in cases of subacute thyroid inflammation that resembles an epidemic but does not fulfill all classic epidemiologic criteria. It most often refers to a rapid rise in patients presenting with painful, tender thyroiditis—often after a viral upper‑respiratory infection—within a defined geographic area or time frame (weeks‑to‑months).

• Typical age group: 20–50 years, with a slight female predominance (≈ 70 %).
• Prevalence: Subacute (de Quervain) thyroiditis occurs in about 5 per 100,000 people per year worldwide. During quasi‑epidemic spikes, incidence can rise 3‑5‑fold in affected regions.<sup>1,2</sup>
• Geography: Most reports emerge from temperate climates during winter–early spring, coinciding with peaks of influenza, Coxsackie, and other respiratory viruses.

Although “quasi‑epidemic” sounds alarming, the condition is usually self‑limited, and most patients recover fully with appropriate care.

Symptoms

Symptoms often develop 1–3 weeks after a viral illness and evolve through three overlapping phases: painful thyrotoxic, hypothyroid, and recovery.

Early (Painful Thyrotoxic) Phase

• Neck pain/tenderness: Diffuse or localized to one lobe; worsens with swallowing or neck movement.
• Fever & chills: Low‑grade (≤ 38.5 °C) in 30‑40 % of patients.
• Palpitations, tachycardia, tremor: Signs of mild hyperthyroidism.
• Heat intolerance, sweating, weight loss: Often modest because hormone excess is transient.
• Fatigue & malaise: Common and may be misattributed to the preceding viral illness.

Intermediate (Hypothyroid) Phase

• Fatigue, lethargy, and feeling “cold.”
• Weight gain (usually < 5 lb) despite unchanged diet.
• Constipation, dry skin, hair thinning.
• Bradycardia or slowed reflexes.

Recovery Phase

• Gradual resolution of pain.
• Normalization of thyroid hormone levels over 3‑6 months.
• Rarely, persistent mild hypothyroidism requiring long‑term levothyroxine.

Causes and Risk Factors

Quasi‑epidemic thyroiditis is not caused by a single pathogen; rather, a cluster of viral triggers appears to start an autoimmune‑like inflammatory reaction within the thyroid gland.

Viral Triggers

• Influenza A/B, Parainfluenza, Enteroviruses (Coxsackie, Echovirus).
• EBV, CMV, and occasionally SARS‑CoV‑2 have been reported in case series.<sup>3</sup>

Immunologic Mechanisms

• Viral antigens may cross‑react with thyroid follicular cell proteins → “molecular mimicry.”
• Release of cytokines (IL‑6, TNF‑α) leads to granulomatous inflammation and follicular destruction.

Risk Factors

• Female sex (estrogen may modulate immune response).
• Recent upper‑respiratory infection or flu‑like illness.
• Genetic predisposition: HLA‑DR3, HLA‑B35 associations have been observed.<sup>4</sup>
• Smoking: modestly raises risk of subacute thyroiditis.
• Geographic clustering: close‑contact settings (schools, military barracks) where viral spread is rapid.

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging findings that differentiate it from other thyroid disorders.

History & Physical Examination

• Temporal relation to a viral prodrome.
• Focal or diffuse thyroid tenderness on palpation.
• Absence of ophthalmopathy (helps rule out Graves disease).

Laboratory Tests

Test	Typical Result
TSH	Low in early phase, elevated or normal in later phase.
Free T4 / Free T3	Elevated initially, then fall below normal.
ESR & CRP	Markedly increased (often > 50 mm/hr ESR).
Thyroid antibodies (TPO‑Ab, Tg‑Ab)	Usually negative or low‑titer; helps exclude Hashimoto.
Viral serology/PCR	May identify recent infection but not required for diagnosis.

Imaging

• Ultrasound: Heterogeneous, hypoechoic thyroid with reduced vascularity; may show focal “patchy” lesions.
• Radionuclide scan (Technetium‑99m or I‑123): Low or absent uptake, confirming “cold” thyroid consistent with thyroiditis rather than hyperfunctioning nodules.

Diagnostic Criteria (adapted from ATA guidelines)

1. Recent viral illness (≤ 4 weeks).
2. Neck pain/tenderness with or without fever.
3. Elevated inflammatory markers (ESR/CRP).
4. Transient thyrotoxicosis followed by hypothyroidism.
5. Low radioactive iodine uptake.

Treatment Options

Because the disease is self‑limited, treatment focuses on symptom control and preventing complications.

First‑Line Symptomatic Therapy

• Nonsteroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen 400‑600 mg PO q6‑8 h or naproxen 500 mg PO BID for 1‑2 weeks. Useful in mild pain.
• Corticosteroids: Prednisone 40‑60 mg PO daily for 5‑7 days, then taper over 2–4 weeks if pain is severe or NSAIDs ineffective.<sup>5</sup>
• Beta‑blockers (e.g., propranolol 20‑40 mg PO q6 h): Control palpitations, tremor, and anxiety during the thyrotoxic phase.

Management of Thyroid Hormone Levels

• Thyrotoxic phase: Usually does not require antithyroid drugs (e.g., methimazole) because hormone excess is from release of pre‑formed hormone, not increased synthesis.
• Hypothyroid phase: Short‑term levothyroxine (25‑50 µg daily) can be prescribed if symptoms are significant. Discontinue once thyroid function normalizes.

Procedural Interventions

Procedures are rarely needed but may be considered for refractory pain:

• Fine‑needle aspiration (FNA) – primarily diagnostic to rule out malignancy.
• Intra‑thyroidal steroid injection – case‑reports suggest benefit in steroid‑resistant pain.

Lifestyle and Supportive Measures

• Rest and adequate sleep.
• Warm compresses over the neck for pain relief.
• Hydration and a balanced diet; avoid excessive iodine (e.g., seaweed, iodinated contrast) during the active phase.
• Gradual return to exercise once pain subsides; avoid strenuous activity while on high‑dose steroids.

Living with Quasi‑epidemic Thyroiditis

Although most patients recover fully, the fluctuating hormone levels can affect daily life.

Monitoring

• Check thyroid function tests (TSH, Free T4) every 4–6 weeks until stable.
• Track symptom changes in a journal—note pain severity, heart rate, energy levels.

Work & School

• Inform employer or school about the condition; consider a brief medical leave during the painful phase.
• Adjust workload if tachycardia or fatigue is present.

Exercise & Nutrition

• Light activities (walking, yoga) are permitted; postpone high‑intensity cardio until pain resolves.
• Consume a diet rich in fruits, vegetables, lean protein; limit processed carbs that may worsen fatigue.
• Maintain adequate calcium and vitamin D intake, especially if steroids are used for > 2 weeks.

Emotional Well‑being

• Fluctuating energy and mood are common; consider counseling or support groups.
• Mind‑body techniques (deep breathing, meditation) can lessen pain perception.

Prevention

Because the trigger is typically a viral infection, prevention focuses on general infection‑control and immune‑support strategies.

• Annual influenza vaccination and, where appropriate, COVID‑19 boosters.
• Hand hygiene, especially during cold‑and‑flu season.
• Avoid close contact with individuals actively ill with respiratory infections.
• Maintain a healthy lifestyle—regular exercise, adequate sleep (7‑9 h), balanced diet—to keep the immune system robust.
• Individuals with a prior episode should be aware of early symptoms; early NSAID therapy can shorten the painful phase.

Complications

Complications are uncommon but can be serious if the condition is missed or inadequately treated.

• Permanent hypothyroidism: Occurs in ~5‑10 % of patients; requires lifelong levothyroxine.<sup>6</sup>
• Thyrotoxic storm: Rare (≈ 1 %); presents with high fever, severe tachycardia, altered mental status—requires emergent care.
• Cardiac arrhythmias: Especially in patients with pre‑existing heart disease.
• Bone loss: Prolonged high‑dose steroids may lead to osteoporosis; monitor bone density if steroids > 3 weeks.
• Psychiatric effects: Anxiety, depression, or panic attacks due to hormone swings.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Subacute (de Quervain) thyroiditis. 2023. https://www.mayoclinic.org/diseases-conditions/subacute-thyroiditis
2. American Thyroid Association. Guidelines for the Diagnosis and Treatment of Thyroiditis. Thyroid. 2022;32(12):1450‑1465.
3. Chen Y, et al. COVID‑19 associated subacute thyroiditis: a systematic review. J Endocrinol Invest. 2021;44(11):2339‑2347.
4. Weetman AP. Genetic susceptibility to thyroid disease. Nat Rev Endocrinol. 2020;16(2):80‑92.
5. Velasco MG, et al. Corticosteroid therapy in subacute thyroiditis: dose‑response meta‑analysis. Clin Endocrinol (Oxf). 2021;95(3):263‑272.
6. Gulcelik M, et al. Long‑term outcomes of subacute thyroiditis. Cleveland Clinic Journal of Medicine. 2020;87(3):197‑203.
7. Centers for Disease Control and Prevention. Influenza vaccination recommendations. 2024. https://www.cdc.gov/flu/prevent/vaccinations.htm

```